Usefulness of abciximab for treatment of early coronary artery stent thrombosis

Ivan P. Casserly, David Hasdai, Peter B. Berger, David R. Holmes, Robert S. Schwartz, Malcolm R. Bell

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

The clinical and angiographic outcomes of 10 patients' who received abciximab as part of their therapy for early stent thrombosis was compared with 25 patients (using historical controls) who received conventional therapy. Although the angiographic outcome and the incidence of myocardial infarction in both groups was similar, there were no deaths or referral for emergency coronary bypass surgery in the abciximab-treated group versus 3 deaths and 10 referrals for emergency bypass surgery in the conventionally treated group.

Original languageEnglish (US)
Pages (from-to)981-985
Number of pages5
JournalAmerican Journal of Cardiology
Volume82
Issue number8
DOIs
StatePublished - Oct 15 1998

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Usefulness of abciximab for treatment of early coronary artery stent thrombosis'. Together they form a unique fingerprint.

Cite this